Kim HS, Park SY, Park CY, Kim YT, et al. A multicentre, randomised, open-label, parallel-group Phase 2b study of belotecan versus topotecan for recurrent ovarian cancer. Br J Cancer 2020 Sep 30. pii: 10.1038/s41416-020-01098.
PMID: 32994466